Compositions and methods for detecting and treating high grade subtypes of uterine cancer

Patent metadata

Field	Value
Publication number	US-12116637-B2
Application number	US-202117380876-A
Country	US
Kind code	B2
Filing date	Jul 20, 2021
Priority date	Jul 24, 2020
Publication date	Oct 15, 2024
Grant date	Oct 15, 2024

Abstract

The present invention relates to methods and biomarkers for detection and characterization of conditions associated with aberrant function of the PPP2R1A subunit of the PP2A protein (e.g., high grade subtypes of uterine cancer) in biological samples (e.g., tissue samples, blood samples, plasma samples, cell samples, serum samples), and related methods of treatment. In particular, the present invention provides compositions and methods for characterizing a patient as having such a condition by identifying mutations in the PPP2R1A subunit of the PP2A gene or gene products, and related methods of treatment through administering to such a patient a DNA Damage Response Pathway (DDR) modulating agent (e.g., a ribonucleotide reductase inhibitor).

First claim

What is claimed is:

1. A method of treating uterine serous carcinoma in a subject, comprising:
detecting in a sample obtained from the subject a P179R and/or S256 mutation within the PPP2R1A subunit of the PP2A gene, wherein the presence of the mutation in the subject indicates a high grade uterine serious carcinoma; and
treating the subject having a P179R and/or S256 mutation within the PPP2R1A subunit of the PP2A gene by administering to the subject a ribonucleotide reductase inhibitor selected from clofarabine and cladribine.

2. A method, comprising:
(a) evaluating a sample containing nucleic acids obtained from a subject having uterine serous carcinoma to detect the presence of one or more mutations in the PPP2R1A subunit of the PP2A gene, wherein evaluating comprises hybridizing to a PPP2R1A subunit of the PP2A gene nucleic acid an oligonucleotide comprising a nucleotide sequence complementary with one or more PPP2R1A subunit of the PP2A gene mutations, wherein the one or more PPP2R1A subunit of the PP2A gene mutations are nucleic acid sequence mutations selected from the group consisting of P179R or S256F;
(b) detecting a P179R or S256F mutation in the PPP2R1A subunit of the PP2A gene in the sample; and
(b) administering a treatment to the subject having the mutation within the PPP2R1A subunit of the PP2A gene, wherein the treatment comprises administration to the subject a ribonucleotide reductase inhibitor selected from clofarabine and cladribine.

3. The method of claim 2 , wherein said nucleic acid from the individual is RNA and the PPP2R1A subunit of the PP2A nucleic acid is cDNA.

4. The method of claim 2 , wherein said sample is selected from the group consisting of blood, serum, and plasma.

5. The method of claim 2 , wherein the sample is a uterine tumor tissue sample.

Assignees

• Univ Michigan Regents

Inventors

• O'Connor Caitlin
• Narla Goutham

Classifications

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• A61K31/7076

  containing purines, e.g. adenosine, adenylic acid · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title